Summary.-The Medical Research Council has for some years encouraged collaborative clinical trials in leukaemia and other cancers, reporting the results in the medical literature. One unreported result which deserves such publication is the development of the expertise to design and analyse such trials. This report was prepared by a group of British and American statisticians, but it is intended for people without any statistical expertise. Part I, which appears in this issue, discusses the design of such trials; Part II, which will appear separately in the January 1977 issue of the Journal, gives full instructions for the statistical analysis of such trials by means of life tables and the logrank test, including a worked example, and discusses the interpretation of trial results, including brief reports of 2 particular trials.
, which are so simple that they are easily mastered by non-statisticians, are commonly more accurate and more sensitive than any of the elaborate alternatives that have been considered. Part II of this report, which will appear in the next issue, describes these two techniques in sufficient detail for them to be performed entirely without statistical guidance. Part I, in this issue, explains, without using specialized statistical language, statistical ideas about numbers of patients, withdrawals, stratification and so on. So that no reference to any other papers or tables should be necessary, even such commonplace statistical things as chi-square (in Part II) and random number tables are supplied and explained.
This report addresses itself to the more quantifiable aspects of clinical trialstreatment comparisons, treatment toxicities, treatment effects in special subgroups, recognition of prognostic features, and so on-while ignoring the important indirect benefits of clinical trials. For example, there is variation in clinical practice between different hospitals, and in a collaborative trial this is likely to be discussed, leading perhaps to a valuable exchange of ideas and to some improvements. Even if this does not occur, the imposition of a treatment schedule actually confers a freedom from having to devise separately each detail of treatment for each different patient, which may make patient management easier and, perhaps, more successful. Another indirect benefit is that a pattern may be noticed in the data which, even if it could well be due just to chance, suggests a line of thought which proves fruitful in this, or some future, study.
It would be unfortunate if our later emphasis on definite answers and large trials were to dissuade prospective organizers from planning a small clinical trial in a hitherto little-studied condition if the alternative is no trial at all. However, most small trials could, with profit, be larger if the organizers attempted collaboration with other hospitals.
The detail needed to explain a concept such as the P-value to readers who are not clear about its true meaning and usefulness would be tiresome to readers who are, and so both parts of the report are divided into sections, each preceded by a sentence summarizing it, so that the whole thing can be looked through without wasting time reading sections which are already understood: likewise, because of the contents list and section summaries, particular details (e.g. arithmetic techniques) should be easy to refer to, if only these are wanted. The report may help physicians to dispense with specialized statistical advice on some occasions, and make more critical use of it on others. It should also be of interest to statisticians who have not yet specialized in such data. For statistical readers, a series of " statistical notes " is referred to throughout the text. These are collected together at the end so as not to distract the general reader from the main text, which is self-sufficient without them.
The collective noun for statisticians is said to be " A variance of statisticians ", and so, although the whole report is largely consensual, some of us may differ from it in certain particulars, as may some members of the committee to which it is addressed.
2.-Event times
Whatever index of failure is of interest, one should not only count how many people " fail " but also see when they failed.
A common form of clinical trial compares treatments which are intended to prevent or delay death from a particular disease. If the course of the disease is very rapid (e.g. acute liver failure) and it is unimportant whether a dying patient lives a few days longer or not, a count of the numbers of deaths and survivors on each treatment is all that is required. However, if (as with most forms of neoplastic disease) an appreciable proportion of the patients do die of the disease, but death may take some considerable time, it is possible to achieve a more sensitive assessment of the value of each treatment by looking not only at how many patients died, but also at how long after entry they died. The best way of doing this is quite simple, but it is easy to overlook when first confronted with the problem. This also applies to any clinical trial which is concerned with the prevention of some other untoward " event " (or " endpoint ") that may eventually affect some or all of the patients. If these events may not occur for some time after starting treatment, it is worth looking at the times at which the events occur as well as counting the number of events in each group of patients. The sort of untoward events which could be studied in such a clinical trial might be myocardial infarctions, leukaemia relapses, strokes, metastatic developments, death from one of a certain set of specified causes (ignoring deaths from other causes), transplant rejection episodes and so on. In each of these studies, it is usually possible to do a more informative analysis than a simple tabulation of the numbers of patients on each treatment who suffered the event of interest. Whether this event is death or local solid tumour recurrence or something else, the design principles and statistical methods are virtually the same:
we observe and make use of the times at which each patient who suffers the event of interest (first) does so. DESIGN 3.-Numbers of patients required Study of a few dozen patients can in most cases detect an ideal treatment which prevents more than two-thirds of the deaths, but more realistic effects, such as preventing about one-third of the deaths, requires well over 100 patients to be detected.
The essence of performing a successful clinical trial is to enter a sufficient number of patients. In theory, a small trial may produce significant results; a total of 10 patients, 5 given one treatment and 5 another, could yield a result which is statistically significant at the 1% level*, if in one group all 5 die and in the other group all survive. But, in practice, trials comparing survival times among only a few patients often just confuse issues or lead subsequent research in fruitless directions, unless there is an all-or-nothing difference between the effects of the treatments being compared, as apparently, for example, in Willoughby (1974) .
There is sometimes a need for a small pilot trial in which treatment schedules are adjusted to acceptable levels of cytotoxicity and of toxicity to the patient before they can be tried out in a large trial, but uncontrolled preliminary trials to get a rough idea of the long-term efficacy of a certain treatment prior to a large trial can be as misleading as any other small trial (Chalmers, 1975) .
Clinical trials are not as sensitive as one would suppose to quite substantial differences between treatments, because random differences between different groups of patients are so much larger than one might expect (Fig. 1) . In clinical trials of time to death (or of the time to some other particular " event "-relapse, metastasis, first thrombosis, stroke, recurrence, or time to death from a particular cause), the ability of the trial to distinguish between the merits of two treatments depends on how many patients die (or suffer a relevant " event ") rather than on the number of patients entered. A study with 100 patients, 50 of whom die, is about as sensitive as a study with 1000 patients, 50 of whom die. a trial to distinguish between 2 treatments also depends, obviously, on how extreme the difference between the 2 treatments is. The exact dependence on the magnitude of this difference and on the number of patients who have to die (or suffer a relevant " event ") is described in Appendix 1. Before examining Appendix 1 carefully, let us consider 2 hypothetical situations. First, suppose there are 2 treatments to be compared, that we are interested in their effects on death rather than on any other endpoint, and that the better treatment prevents or substantially delays one-third of the deaths that would occur on the other treatment: in other * This would be true using almost any statistical method. The exact meaning and practical utility of significance levels (" P-values ") is discussed later. 588 litillitillitill words, the death rate ratio (better: worse) is 2: 3. The better treatment is thus a very important medical advance over the other treatment, and it would be extremely important that so marked a therapeutic improvement should be clearly demonstrated and widely accepted. Unfortunately, advances in therapy as marked as this are not common, and few of the organizers of the many hundreds of clinical trials currently in progress are lucky enough to be studying a 2:3 ratio in mortality.
In the second hypothetical situation, we shall suppose that the improvement is even better, and that the death rate ratio is 1: 3. In other words, suppose we have discovered an excellent treatment which prevents or substantially delays most of the deaths which would occur on the other treatment. This is probably an unrealistic hypothesis, but it will help illustrate the limitations of clinical trials. Now let us refer these 2 situations to Appendix 1, to discover how large a clinical trial must be to demonstrate treatment differences in these 2 hypothetical instances. In the second hypothetical situation, where the death rate ratio is 1: 3, the sort of small trial that a single large centre might organize alone, in which a few dozen patients are randomized and 20 of them die, has an even chance of demonstrating a significant (at 5%/ level) difference (and, therefore, an even chance of failing to do so). If enough patients were randomized for 40 deaths to be observed, however, there would be an 80% chance of a statistically significant result, and, even if the result happened unfortunately not to be statistically significant, the group given the better treatment would almost certainly have fared substantially better than the other group.
What of the more realistic situation, in which the death rate ratio is only 2:3? This would still be of great medical importance, but the before) but because many children died for other reasons, the overall death rates were not initially reduced very much. Clinical trials in which the influence of treatment on time to death is of prime interest should rarely be undertaken unless either there is some hope that the death rate can be halved, or the trial will be able to continue until at least 100 patients have died, which will usually require the admission of well over 100 patients. There are exceptions, of course (the chief one being when the disease is so rare that large trials are impossible, even if many hospitals collaborate), but it is unusual for the comparison of the times to death of a smaller number of patients to be of much value, unless (as might be the case if no large series of such patients had yet been reported) the chief point of the trial is not the comparison of 2 treatments but rather the study of the natural history of the disease. Moreover, the patients may need to be entered over a reasonably short time, if the trial is not to be overtaken by results from other trials. Because of this, in all but the commonest diseases, no one physician or even hospital department will be able to complete alone a successful trial studying survival duration. Cooperation between independent physicians in different hospitals is often essential. * It would undoubtedly be better if the organizers of most of the hundreds of different small trials currently in preparation or progress at single centres around the world attempted to secure the collaboration of colleagues at other centres in randomizing patients into their trials. Sometimes quite a small organizational effort can double or more than double the size of a given trial by recruitment of other centres at which, otherwise, no sort of a trial would have been running. It is wrong for research-oriented centres to disdain such collaboration from centres which are not research-oriented, even if the standards of medical management are presumed not to be quite as good as at the research-oriented centre. In fact, since the success of a trial depends so strongly on the numbers of patients randomized, it should perhaps be emphasized when soliciting collaboration that all physicians who do collaborate wholeheartedly will be full co-authors of any eventual publications. (Windhorst, 1976) , and has commissioned a compendium which is supposed to be updated every 3 months of all clinical trial protocols, including those on the European lists; the first issue of this has just appeared (Smithsonian Corporation, 1976 Finallv, the commonest reason for deviations from schedule in cancer trials is probably treatment toxicity, necessitating that less than the specified dose be given or that courses of treatment be delayed. Specification of schedules should therefore include details of what to do if undue toxicity emerges: practicable, flexible schedules avoid many " deviations " and are more relevant to real medical practice, as long as the reasons for " flexibility " are clearly formulated.
5.-Significance levels (" P-values ") "P 0-05 " does not mean " the probability that the treatments are equivalent is 0 05 ".
There are fewer sources of error and bias in a randomized study than in a non-randomized study, but even with proper randomization misleading results can emerge.
If a group of patients treated one way does better than another group which was treated in another way, there are 2 possible explanations for this: either the first group got better treatment, or the first group contained disproportionately many patients who would have done well anyway, even if they had been treated in exactly the same way as the second group. Unfortunately, division of patients into 2 treatment groups by randomization is no guarantee that the 2 groups have equal proportions of patients with good and bad prognoses, and so, even in a random-ized trial, spurious differences between treatments will sometimes arise. The whole elaborate clinical trial machinery of randomization, objective assessment, avoidance of losses to follow-up, and so on, however, ensures that if a substantial difference emerges between the average outcomes in the 2 treatment groups, then we can calculate the probability of getting a difference at least as substantial as this by chance alone if the 2 treatments are in fact equivalent. This probability is called the "significance level ", or " P-value ". Even if the 2 treatments are exactly equivalent, our random allocation may, by chance alone, put more of the goodprognosis patients on to one treatment than on to the other. The exact meaning of the familiar abbreviation " P < 0 05 " is thus " the patients in one treatment group have fared better than the patients in the other. If there is no difference between the medical effects of the 2 treatments and the only cause of differences between the treatment groups is the chance allocation of more goodprognosis patients to one group than to the other, then the chance of one treatment group faring at least this much better than the other group would be less than 0 05, i.e. less than a 1 in 20 chance. " It is worth the effort of understanding this convoluted statement, since the logic of it contributes to so much modern medical research. (It does not, for example, mean that the probability that there is no difference between the treatments is 0.05.) A significance level is, it may be seen, an extremely indirect answer to a physician who simply wants to know which treatment works best (especially since events with probability less than 0 05 are really quite plausible: throwing double 6 with a pair of dice, for example), but it is better than no such answer at all. To calculate the significance level, it is not necessary that exactly similar proportions of patients with bad, medium and good prognoses were allocated to each treatment. What is necessary is merely that the probability of a trial patient getting one or other treatment be independent of whether that patient has a bad, medium or good prognosis, and that the standard of assessment of success or failure be independent of treatment. This means that stratified allocation (which is discussed later) is not necessary, but randomized allocation is.
6. Further reasons for large trials k given P-value in a large trial is usually stronger evidence that the treatments really differ than the same P-value in a small trial of the same treatments would be.
There are hundreds of well-conducted clinical trials now in progress, which are comparing 2 essentially equally effective treatments. Unfortunately, at least 1 in 20 of these null trials will report a misleadingly significant (P < 0.05) difference. Conversely, many of the trials which are now comparing 2 genuinely different treatments will not observe a "significant " difference. How, then, should claims of " statistical significance " be assessed, when it is common experience that many early claims are later refuted? In classical statistical theory, only 2 criteria the P-value and the intrinsic plausibility of the claim which the P-value supportsare supposed to be balanced, but in assessing these to decide whether or not the 2 treatments really differ at all, the size of the trial is an additional, independent, third criterion. Let us consider this in the context of a trial where a new treatment is being compared with, as control, a standard treatment.
Nowadays, for every trial that compares 2 treatments which are substantially different, there are probably 5 to 10 " null " trials in progress comparing 2 treatments which are almost equally effective. Moreover, even the " substantial" differences are by no means so substantial that small trials can reliably detect them: it might be, for example, that when 5000 of the control patients are dead, only 3300 of the patients receiving the new treatment would be expected to have died. A difference of this magnitude has over 95% chance of being detected in a trial in which hundreds of patients are randomized and about 250 of them die, but only a 25% chance of being detected in a small trial in which dozens of patients are randomized and about 25 of them die.
We need now only to postulate a few reasonable numbers to see the effects of this situation (Table I) . Three immediate consequences of the numbers in Table I discover whether a new treatment is better than the standard treatment, and to answer no other questions, the normal practice is to randomise (1: 1 or perhaps 2:1) and to compare the fates of the 2 groups. However, some people prefer to put all the patients on to the new treatment and merely to see if they fare better than previous " such " patients. The advantages are that randomization, which is sometimes difficult to explain to the patient, is avoided; the group getting the new treatment is bigger than it would have been, since it now includes all the patients who would have been controls; and that the " control " group is bigger still, comprising many other patients from previous series. The overwhelming disadvantage is that there may very well be systematic differences between the old series and the treated series due to changing referral patterns to the study centre, changes in supportive therapy, changes in the skill of the doctors, or subconscious (or even conscious!) selective biases: for example, the omission of a few old or moribund patients from the new series can make a big difference to the overall outcome. Byar et al. (1976) , in a readable paper on this and other aspects of clinical trial methodology, give a nice example of 2 large series of prostatic cancer patients, selected by the same criteria at the same centres, both given placebo yet differing substantially in survival. Likewise, S. J. Pocock has collected 19 unselected other instances where consecutive trials in the same malignant disease at the same collaborating centres carried over a common treatment arm from one trial to the next. The results when one arm was compared with the supposedly identical arm in a later trial were often materially different; 10 of the 19 2-tailed P-values were less than 0-2 (as opposed to 4 expected by chance), and 3 were less than 0 02.
From However, unless a trial is seen by the investigators only as a " pilot " trial, a precursor to a future randomized study, it is probably wise to randomize, and Chalmers (1975) , in a delightful 3-page paper, argues that even pilot trials should be controlled by randomization. A reasonable compromise for someone intent on a major study using only " historical controls " would be (unless the new treatment is so confidently preferred that randomization is felt to be unethical) to randomize in the ratio 2: 1. Two-thirds of the patients are still available for comparison with whatever " his- " Blind allocation ", in which the patient is unaware of which treatment he is receiving, and " double-blind allocation ", in which both the patient and physician are unaware, are sometimes excellent devices for helping ensure that response is assessed objectively, and whenever assessment of the response of interest is subject to much uncertainty it is worth considering whether the treatments could be formulated effectively in ways which appear indistinguishable to the patient, the physician, or both. Alternatively, " blind assessment " of a subjective response by another physician, who really is unaware of the treatment being given, may be of value. A subjective response, such as "disease stasis " or "escape from disease stasis ", in solid tumour therapy should either be avoided, or assessed in as objective a manner as possible.
11.-Treatment allocation Balanced randomization at the latest possible time is recommended, with no stratification; Appendix 2 gives practical details of how this is done.
At the start ofa trial, each participating centre may be given an ordered set of sealed envelopes. A preferable technique is to keep the envelopes at a central office and to make the separate centres telephone for instructions when a new patient is to be randomized. This uses more administrative time, but it does avoid all suspicion that any form of cheating has occurred, and it leaves no doubt at the central office about exactly who has and who has not been admitted to the trial. Each envelope contains the instruction as to which treatment schedule to follow for a particular patient. When a patient who appears to satisfy the admission criteria is found, he is formally admitted, and only then is the envelope opened to discover his treatment.
If randomization is to be by reference to a central office, a simple randomization list may be constructed instead of a set of envelopes, as long as this list, which specifies the order in which treatments will be allocated throughout the trial, will never be seen by any physicians responsible for patient entry, including any trial organizers who also treat patients.
If the treatment -to be given to the next trial patient is known before the biased analysis of most such trials can usually only be guaranteed if all deaths occurring in either treatment group after randomization count against that groupeven including deaths during the early period, when patients in both groups should be being treated identically! If, therefore, randomization takes place well before the patients in the 2 groups have to be treated differently, chance differences in what happens in the early (common) period may dilute real differences in the later period. Randomization should, therefore, usually take place as late as possible, and analysis should preferably compare the totality of postrandomization mortality in one group with that in the other. These rules also apply in clinical trials of whether to stop regular anti-cancer treatment in patients who have been apparently free of disease for some time. It is preferable to count the total number of post-randomization deaths in each group, even if randomization occurred after slightly different disease-free periods in different patients. It is therefore generally preferable to randomize as late as possible, so that almost immediately after randomization the patients in different groups will start to receive different treatments. Likewise, in trials comparing different treatments for the relapse of previously controlled disease, wait until relapse actually occurs before randomizing.
The order in which the treatment schedules appear in the sealed envelopes should ideally be:
(1) Unpredictable, in the sense that the physician may know that the overall ratio is 2:1, 1:1, 1:2 or whatever, but given this, he has no further idea what the next envelope contains. (2) Balanced, so that when the trial stops, the numbers of patients on the 2 treatments are roughly in the desired ratio. (3) In addition, it would be an advantage if the patients with good and bad prognoses were also each balanced in the same ratio between the treatment groups.
A variety of allocation schemes can be devised, ranging from simple coin tossing to elaborate " stratification " schemes in which a separate series of envelopes is provided for each of several prognostic categories of patient*. However, proper statistical methods, such as those which will be introduced later, make due allowance when comparing 2 treatments for what was initially known about each patient. (This may be thought of as " retrospective stratification ".) If proper methods of analysis will be used, stratified entry makes little difference, and it is usually completely satisfactory to have a single series of envelopes for all patients, and not to bother to " stratify " in any way. This is discussed further in the next section. How should the sequence of treatments in these envelopes then be determined? The difficulty is that, unless the numbers are large, the requirements for (1) unpredictability and (2) balance are to some extent incompatible. Because of this, some statisticians say " Randomize: that's the only way to achieve complete unpredictability " (which is true), while others (like us) say: " Constrain the randomization to keep the proportions allocated to the 2 groups reasonably close to your chosen proportions." (Statistical Note 2, on p. 611, discusses, but does not recommend, other, more complex, allocation rules.) The disadvantage of randomizing if your chosen proportions are, say, 1: 2 is that you may end up analysing a very lopsided trial with 5 out of 30 on one treatment instead of an intended 10 out of 30. For this reason, complete randomization should not usually be used, unless the intended allocation ratio is 1: 1, in which case it is fairly safe, even though pseudorandomization may still be preferred: see Appendix 2. The disadvantage of pseudo-randomization is that the physicians may see through the scheme, work out the next treatment, and so admit different types of patient to the 2 treatments, but we have never known of this happening.
The practical details of both methods are trivial: to produce 100 envelopes randomized in the ratio 1: 1, you toss a coin 100 times, getting a series of letters A (for heads) or B (for tails), and then you make up the envelopes in the order specified by your list, keeping the list to check that the physicians use the envelopes correctly and obey them. To produce 100 envelopes pseudo-randomized in the ratio 2:1, 1:1 or 1:2, you may use the methods described in Appendix 2. In a multi-centre trial, it is slightly preferable to have a balanced allocation list (see Appendix 2) for each separate centre, especially if the number entered by some centres is very small. This form of stratification involves no extra trouble whatever for the participating centres, and actually helps maintain their interest, by ensuring that each centre is called on to administer each treatment.
12.-Should " 8tratifted " allocation be envisaged?
If, during analysis, initial prognosis will be allowed for while the different treatments are being compared, there is hardly ever need for stratification at entry in large trials.
As long as good statistical methods, such as those given in Part II of this paper, are used to analyse data from clinical trials, there is no need for randomization to be stratified by prognostic features. Moreover, if the organizational complexity of it deters any collaborators from entering patients during busy clinics (or deters * If each of these separate series of envelopes is completely random, no improvement in balance whatever is obtained by such " separate randomization ": the treatment prescriptions in each particular such series of envelopes must therefore alternate, or have some other such constraint imposed on them, if stratification at entry is to have any effect whatever. them completely from collaboration in this or in some future trial), positive harm will have been done by the initial stratification. These views are not generally accepted, so in this section we argue them at greater length than many readers will wish to follow. If you agree that stratified randomization is usually unnecessary (except, perhaps, in very small trials), or if you are indifferent on the matter, skip this section.
Usually, for purposes of statistical analysis, the patients will be subdivided into a few strata, defined retrospectively from those features (e.g. age or stage) which are eventually found to be really relevant to prognosis. The points of subdivision of each such feature can be chosen in the light of the actual data, to make the prognostic discrimination most sharp, and certain groups with a similar prognosis may finally be merged. The patients within one stratum will then be compared with each other, to see if treatment appears to have been beneficial, and the comparisons within each stratum will finally be combined to give a single overall P-value for the effects of treatment adjusted for initial prognosis (see Appendix 3 in Part II for a worked example).
If the distribution of treatments is similar in each stratum, no actual bias is corrected by such " retrospective stratification ", but the fact of comparing like with like makes such an analysis slightly more sensitive. Suppose now, that we stratify at entry, randomize with " balanced " random numbers within each initial stratum (or assign treatments by alternation within each stratum), and suppose further that, by luck and good judgement, the initial strata are all subsets of the retrospective strata which we devise during the eventual statistical analysis of the data. Retrospective stratification will still have to be undertaken, for if no allowance is made in a statistical analysis for the fact of stratified entry, the calculated P-values are not extreme enough. The only advantage gained by stratification at entry is that, within each retrospective stratum, reasonable balance between the numbers on each treatment will automatically be achieved, and a wasteful situation, where almost all the patients in one retrospective stratum happen to get the same treatment, is avoided. This advantage, however, is largely illusory, unless the trial is very small. The improvement in the sensitivity of a clinical trial to be expected from achieving perfect balance between the numbers on each treatment in each restrospective stratum, instead of letting them be defined by chance, is just that to be expected from randomizing a single extra patient into each retrospective stratum. (This is proved in Statistical Note 3 on p. 611.) However many initial strata are defined, only a few retrospective strata will be needed, and so the expected benefits from initial stratification are-slighter than would intuitively be expected; indeed,-if the organizational complexity of stratification at the time of randomization reduced collaboration at all, a net loss of efficiency would be the likely result. This objection does not, of course, apply to sttatification by centre in a multi-centre trial.
13.-Exclusions, withdrawals, losses, and deviations from treatment Rigorous entry criteria are not necessary for a randomized trial, but rigorous follow-up is. Even patients who do not get the proper treatment must not be withdrawn from the analysis.
Individual physicians will probably have, for certain of their patients, a definite preference for one or other (or none) of the trial treatments. When this happens, the patient cannot ethically be admitted to the trial in case he gets the " wrong " treatment: he must be excluded from the trial, and be given the treatment thought best for him, even if there is little objective basis for this preference.
It is worth including in the trial protocol specific instructions against randomizing patients who are unlikely to tolerate, or who may be unable to receive, any of the treatment schedules (e.g. through having " bad " veins, and thus not able to receive prolonged i.v. therapy), who are extremely old or extremely young for the disease, who seem unlikely to cooperate, who live so far away that regular treatment will prove difficult, or whose disease seems likely to take an abnormal course. Certain of these patients may teach one a lot about the disease, but not through inclusion in a clinical trial. Also, if the disease process is very long, it is best to restrict admission to patients who are likely, as far as one can tell, to continue to attend the same hospital throughout the course of their disease.
It is also best to restrict collaboration to centres thought likely to continue to collaborate seriously for a few years, for if, in a multi-centre trial, some centres lose interest during the first year and start giving trial patients all sorts of different treatments, or stop supplying the necessary follow-up information, the result can be progressive collapse of the whole study. This may be preventable if deviant centres are quickly expelled or quickly asked to reform, but this requires up-to-date monitoring of the study by a group with some moral authority.
In a clinical trial, there are 3 distinct categories of missing patients: those who are excluded before randomization; those who, despite having been randomized, are deliberately withdrawn from the trial as though they had never been entered; and those who are inadvertently lost during follow-up, and whose experience can be included in the statistical analysis only up to the date of loss. There is no agreed terminology for these 3 categories, and we will refer to them as exclusions, withdrawals, and losses, respectively (see Fig. 2 In the foregoing rules (which should be adopted whenever possible), observations made at the time of randomization are used to determine without bias who will be withdrawn. Unfortunately, for example, acute undifferentiated lymphoblastic leukaemia might be mistaken for myeloid leukaemia by all criteria that can be recorded at presentation, and the misdiagnosis might not be recognisable until partial control of the disease has been achieved. The previous rules will not then apply, and there are then only 3 options for the design of such trials:
(1) Do not randomize patients unless or until the differential diagnosis is unequivocal. (This may lose some appropriate patients from the study.) (2) Randomize some or all of those in whom the diagnosis is doubtful, withdrawing any who subsequently proved to have the wrong disease as if they had never been randomized. (3) Again, randomize some or all of those in whom the diagnosis is doubtful, but leave all randomized patients in the final analysis, even those whose diagnosis was revised and whose treatment consequently altered. (This is always valid, and is sometimes the only valid policy, but it is somewhat artificial.)
Option (2) (2) is only invalid if the different treatments will affect the probability of diagnostic revision differently, and this will be the exception rather than the rule. Whatever rules are adopted to deal with the problem of possible misdiagnosis, they should be written into the design of the trial and not invented ad hoc during the statistical analysis to exclude an unwanted patient or two from a particular group.
13C.-Losses and deviations.
Patients who move away from the centres where they were admitted to the trial should not be allowed to disappear from the trial. If possible, their fate should be discovered, perhaps by extensive telephone enquiries, letters, or even special visits by research assistants. (The MRC leukaemia trial policy is to accept no reason, other than permanent emigration from Britain, for loss, and so they try to avoid including foriegn nationals in their trials.)
It is sometimes suggested that if a substantial deviation from the allotted treatment occurs, that patient should not be included when the final comparison of treatments occurs (or should be included only up to the date of deviation). This is seriously wrong, as the group which deviates from one protocol and the group which deviates from the other protocol may be so different in their chances of long survival that the treatment comparison in the remaining patients will be severely biased. Disagreement about this point is perhaps the chief source of misunderstanding between statisticians and clinicians about the logic of trial design. To clinicians who disagree, it might be pointed out that including all the deviants can only affect the conclusions appreciably if the deviants are more numerous in one treatment group than in another, and grossly different in survival duration from the protocol adherents, but in this case exclusion of them is not valid. Withdrawing protocol deviants from the statistical analysis is therefore either irrelevant or invalid in large trials.
A serious error is to exclude from the statistical analysis any post-randomization, pre-treatment deaths in the active treatment group, while retaining all the untreated controls. The safest general rule is always to leave all randomized patients in (and to randomize later in your next trial!) for in a large trial the overall results will only be materially affected by exclusions if there is a discrepancy between the numbers of exclusions in the two treatment groups which is so marked that it suggests their exclusion was invalid.
13D.-Example: retaining deviants.
This has arisen recently in the MRC trial of elective splenectomy in chronic granulocytic leukaemia. Patients with chronic granulocytic leukaemia are randomized to be either splenectomized or not when their disease is in remission. Unfortunately, some of the no-splenectomy group may later develop splenic symptom's which call for splenectomy, and so a few of the patients randomly allocated to no-splenectomy may in fact be splenectomized! Those allocated to the no-splenectomy group who actually seem to need (and therefore get) splenectomy are unlikely to live as long as average, so if we excluded them or if we transferred them from one group to the other group, the 2 groups would no longer be comparable.
The simple comparison of all patients actually splenectomized with all truly non-splenectomized patients is not a valid measure of the value or otherwise of elective splenectomy, as these 2 categories were not separated from each other at random. Neither is a comparison of the group which was randomly allocated for splenectomy with the group which was not splenectomized valid. We must not treat any patient as lost even if that patient has to be splenectomized later on. We must follow all of them to death or to the end of the trial, and then compare the group which was randomized to splenectomy with the group which was randomized to no-splenectomy, whatever subsequently happened to them. This answers the medical question of primary interest, which is whether a policy of splenectomy, if medically possible, is superior to a policy of no splenectomy unless specifically indicated.
When departures from protocols are necessary, clinical trials compare a policy of one treatment as far as possible with another policy, and although it is often of interest to describe the results among the protocol adherents, comparisons which omit protocol deviants cannot be tested statistically.
14.-When to analyse and publish your results Early analysis of a trial can be misleading if a temporary difference, which would have been smoothed out by large numbers, causes the trial to be aborted so that large numbers never accumulate.
Most statistical tests applied to clinical trial data are based on the assumption, usually false, that the decision to stop and publish has been taken completely independently of the current results. This is true of the methods we will describe, and of the methods used in almost all published reports of trials. However, only an investigator with superhuman willpower or completely chaotic records could supervise a clinical trial for months or years without ever looking to see which way the results were drifting, and in practice every now and then at least a cursory impression is usually sought. If no striking difference is apparent, the trial may tick on, but if there is an apparent difference a more formal analysis will be undertaken, and if this is positive, the trial is likely to be stopped and its results published.
Suppose you look every 6 months at a 3-year trial that is comparing treatments which are really equivalent, and ask on each occasion, "Is it significant at the 0 05 level yet?" The chance that it will be on any one particular occasion is 0 05, but unfortunately the chance that it will be on at least one of the 5 occasions is much more than 0.05. If your policy is to look every 6 months and publish if you ever find P < 0.05, then the chance that you will publish a " significant (P < 0.05) difference " in a trial comparing 2 treatments which are, in fact, identical is probably more like 15% than the 5 % which is claimed, and for this reason, most published P-values should be mentally doubled or tripled (McPherson, 1974) . Statistical theory can, by standard methods, compute a P-value on the assumption that no preliminary examination occurred, and statistical theory can, by " sequential " methods, compute a P-value on the assumption that very frequent preliminary examination has occurred, with the intent of stopping the trial when a given difference was reached. (Particular sequential methods for cancer trials are discussed in Statistical Note 4 on p. 611.)
Unfortunately, statistical theory cannot in principle compute a P-value from a trial in which occasional preliminary examination occurred: one can only say that the true significance level must be less extreme than the cited P-value, but not as much less extreme as it would have been had very frequent preliminary examination occurred.
This present state of affairs is not satisfactory, and no easy universal solution exists. One simple rule, that will often help considerably, is to avoid any analysis (or even brief inspection) of the data until some dozens of deaths have accumulated, for it is trials first looked at when very small that are most likely to be misleading. Eventually, the fear that one treatment may be vastly worse will compel inspection, but the longer the delay before first analysis, the smaller the risk of a misleadingly significant difference being discovered when the treatments are really equivalent.
The simplest solution is to continue as at present, where most published P-values need to be mentally doubled. The only completely ethical and valid alternative is for every clinical trial to have a professional statistician, using weekly computerized analyses to administer a sequential design. Because the present article is intended to enable clinicians to design and analyse their trial, without getting tied up in statistical knots, we shall ignore the possibility of using sequential methods, (except for those suggested in Statistical Note 4) and shall describe instead the straightforward, non-sequential analysis of ordinary clinical trial data, despite the drawbacks outlined above.
15.-Ethical considerations Individuals must never be denied clearly appropriate treatment, even if trial protocols are thereby disrupted.
Physicians who are convinced that one treatment is better than another for a particular patient of theirs cannot ethically choose at random which treatment to give: they must do what they think best for the particular patient. For this reason, physicians who feel they already know the answer cannot enter their patients into a trial. If they think, whether for a wise or silly reason, that they know the answer before the trial starts, they should not enter any patients, and if they become convinced that one treatment is better during the course of the trial, they must stop randomizing their patients.
To avoid trials grinding to a halt before any marked degree of statistical significance has been obtained, Chalmers has suggested that it may be necessary to keep the treating physicians ignorant of the current state of the treatment comparison, and only to allow access to the pooled results from all the centres to a small steering committee which decides when the trial shall stop, giving no progress reports whatever on the results until after the trial intake has been halted. (An intermediate alternative, routinely used by Zelen and his colleagues, might sometimes be to give progress reports, with outcome tabulated by treatment, but keeping secret which treatment is which.) The ethical considerations of the supervisory committee can then be guided by slightly wider perspectives than the treating physicians, balancing the damage done by an inconclusive result against the damage done by continuing to allocate some patients to a schedule which appears at the time to be suboptimal. Such a policy has not been adopted by the MRC Leukaemia Steering Committee, partly because so few of our trials have discovered any differences, but we may some day have to do so. This is not an easy matter: any trial which produces good evidence that one treatment is better than another would have produced almost as good evidence had the last patient given the inferior treatment actually been assigned to the other treatment. If the developing trend is already appreciated by the physician before this last patient is randomized, how can allocation to the inferior treatment be justified? Continuation of this argument suggests that serious consideration of each individual patient's welfare will lead to policies which prevent any clinical trial from producing a clear answer,* which, * Unless response is so slow that admission of all patients is complete before the results emerge. paradoxically, will be policies detrimental to the very people they are designed to protect. An ethical imperative exists which is frequently ignored, that we must, if we can, discover how patients can be treated most effectively, and where this requires randomized trials, the apparently irrelevant device of keeping the physicians ignorant of the current results just manages to avert the previous paradox. (Another device which can, in slow diseases such as cancer, help avert it, is to make total entry as rapid as possible, so that entry is finished before any trends can be seen.)
" Blind " trials, where the patient, the doctor, or both, are unaware of which treatment has been given, are frequently easier to organize if placebo treatments are given to the control patients. It is doubtful whether any invasive placebo treatments, involving, for example, dummy injections or infusions, are justifiable, unless a very unusual degree of informed consent has first been given, and the same applies to diagnostic surgery, X-ray investigations, and to bone-marrow (or other) aspirations, if these are of no value to the individual patient.
Finally, of course, it may be ethically necessary not to adhere to a trial schedule which is clearly unsuitable for a particular patient, even though this slightly muddies the scientific comparison of schedules with each other, by diluting one group with people who did not receive the scheduled treatment. In all trials, clinicians must tread a narrow path between unnecessary deviations from protocol and the risks that the protocol may have for the exceptional patient.
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We are grateful to Gale Mead for typing the annual rewrites which this manuscript has suffered since 1971, and to the many colleagues who used and criticized previous versions. It is possible for a clinical trial comparing 2 treatments to produce a " statistically significant " (P < 0 05) difference even if the treatments are, in fact, equivalent in their effects. A far more common mishap is for a comparison of 2 treatments which really are different to fail to reach statistical significance.
However, if there really is a difference between the chances of survival under the 2 treatments, the more patients we put into the trial the more likely we are to get a statistically significant difference, and this Appendix indicates the approximate numbers of patients that must be randomized to have an even chance of a statistically significant outcome when the trial is finally analysed. Of course, the numbers required depend on how big the true difference is, and if you knew that at the design stage you would not be doing the trial anyway! However, in practice, physicians usually have an idea of what differences might well exist between 2 treatments, and this Appendix is intended to be used to ensure that ridiculously small trials are not started (see also main text). Unless you can say " such-and-such a difference might well exist, and if it does we have a better than even chance of detecting it ", you should not start a clinical trial.
Approximately equivalent numbers are usually needed for a null trial result to be useful. Suppose that, in a trial sufficiently large for a given difference to have an even chance of being detected, the 2 groups eventually fare about the same as each other.
You will be able to conclude (with " 95% confidence ") that the real difference could be zero and could be anything up to that given difference in either direction, but that the real difference could hardly be any more extreme than this. If, therefore, that given difference was one which you had previously thought might well exist, your null trial has told you something new, but otherwise it has not.
To use this Appendix, first estimate roughly how many patients you will be able to randomize, and roughly how many of these will die before the trial is analysed. This is because the sensitivity of a clinical trial depends not so much on the total number of patients randomized into the trial, but rather on the number of patients who die before the statistical analysis takes place. Next, refer this projected number of deaths to Table II to see what magnitude oftreatment differences you are competent to characterize. The calculations leading to this table need not be understood, but the conclusions it expresses must be.
For a given degree of superiority of one treatment over the other, Table II indicates the number of patients that must die in a clinical trial for there to be an even chance of a statistically significant difference being observed. Even if the observed difference is not statistically significant, however, it is still likely to be in the right direction (and likely to be nearer being significant than to being zero) and thus, it will probably suggest the correct answer. If the trial size is doubled, the chance of statistical significance rises from 50% to 80%, and even if statistical significance is, unfortunately, missed, there is almost bound to be a substantial difference in the right direction.
Example-If we expect an average intake of 2 acute myeloid leukaemia patients a week, and we expect about half the patients to die within 6 months of entry, half the survivors to die within the next 6 months, etc., then what sensitivity could we expect from a clinical trial, the intake to which lasted one year?
Answer-By the time entry is complete, one year afterentrystarted, about 100 patients will have been randomized, and we might find that about 40 of these patients will already be dead. If Table (Table III) haphazardly with a pencil point, and then starting with the number nearest to the mark thus made), and read off the series of 2-digit numbers from there on. Replace each such 2-digit number by the corresponding letter sequence and use the overall sequence of A's and B's thus generated to specify the order of the contents of your randomization envelopes.
A similar approach to 3-group trials is possible; in order to get a random ordering of 2 A's, 2 B's and 2 C's, proceed as above but, having selected one of the above sequences, use the next 2-digit random number to change one of the A's and one of the B's into C's, as follows: Finally, a similar approach to randomization in the ratio 2:1 or 1:2 is possible: simply produce a balanced sequence of A's, B's and C's as above, and then either change all the C's to A's (for a 2:1 sequence) or change all the C's into B's (for a 1: 2 sequence).
Example-If the mark made by your pencil is nearest to the number 33 in the 3rd row of Table III, the numbers obtained will be 33, 16, 26, 91, 57, 58, etc., Kaplan and Meier (1958) , Mantel (1966) , Peto (1972) , Cox (1972) , and Peto and Pike (1973) , and are reviewed by Breslow (1975) .
STATISTICAL NOTE 1.
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The above considerations apply to that large majority of studies in which there is no real difference or only a moderate real difference, so small that it is likely to be missed by a small trial. However, in those few studies which compare treatments so enormously different that a small trial is likely to detect this, opposite conclusions apply: such trials will necessarily stop when still small, and such differences will therefore only be found among significant small trials. Proper treatment of this whole question requires that a distribution of real differences be postulated, and its consequences considered; as long as this postulated distribution has a large majority of real differences so small that they are unlikely to be detected by small trials, the conclusions stated in the main text remain valid.
STATISTICAL NOTE 2.
(From p. 600.) An alternative sometimes suggested is to vary the probability of allocation of the next patient to each treatment, in the light of the data so far, to make allocation to the apparently better treatment progressively more probable. If, however, there is a tendency for later patients to fare better irrespective of treatment, then datadependent allocation will produce too many extreme P-values comparing treatments which do not really differ, while if the opposite time trend exists, a real superiority of one treatment may be masked. The much larger disadvantage is the possibility of conscious or subconscious cheating in the selection of patients for the trial. At the end of such a trial, the physicians will know that their favourite treatment is doing well, that most new trial patients will now receive it, and that if just a few more patients put on it now do well, the trial will appear conclusive. Severe The advantage of sequential analysis is the guarantee that in the rare cases when one treatment is much worse, the trial will automatically be aborted. However, the advantage of not looking at the results until the last minute is that if, as is more usual, one treatment is only moderately worse (e.g. if the better treatment only reduces the death rate by 50% or less), a statistically significant difference is more likely to emerge than if sequential methods had been used. These advantages might be combined by a policy of not stopping prematurely, unless the chi-square comparing treatments reaches some rather extreme value such as 9 (referring to Armitage's " Repeated Significance Test " designs for the P-value if it does). Otherwise, let the trial run on to a previously agreed final size or date, when ordinary statistical analysis is undertaken. (Correction of the final P-value for the stopping policy is possible, but would usually be unnecessary.) This policy would be peculiarly appropriate for cancer trials, where prolonged follow-up is usual: here, the monitoring would usually be needed only while new patients were still being randomized, since, once this phase is complete, the ethical difficulties of continuing to accumulate follow-up information may be less acute (unless patients could still, with advantage, be switched to the superior treatment late in the course of the disease).
STATISTICAL NOTE 5.
(From Table II .) The death rate among the survivors of a group will in general vary according to how long ago randomization occurred (since an exactly exponential distribution of survivorship is unusual). If, in 2 groups, the death rates vary in parallel, that in one group among the survivors at a given time after randomization being a constant multiple A of the corresponding rate in the other group, then we have a " Proportional Hazard " situation (Breslow, 1975 Peto and Peto (1972) noted that no class of differences exists against which Gehan's (1965) 
